Tornier (Nasdaq: TRNX) reported earnings on May 8. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended April 1 (Q1), Tornier met expectations on revenues and missed expectations on earnings per share.

Compared to the prior-year quarter, revenue increased and GAAP earnings per share expanded to zero.

Margins increased across the board.

Revenue details
Tornier booked revenue of $74.5 million. The nine analysts polled by S&P Capital IQ anticipated revenue of $75.0 million on the same basis. GAAP reported sales were 7.2% higher than the prior-year quarter's $69.4 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $0.00. The five earnings estimates compiled by S&P Capital IQ predicted $0.01 per share. GAAP EPS contracted to zero from the prior-year quarter's -$0.68.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 71.6%, 50 basis points better than the prior-year quarter. Operating margin was 1.7%, 60 basis points better than the prior-year quarter. Net margin was -0.2%, 3,430 basis points better than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $69.5 million. On the bottom line, the average EPS estimate is -$0.01.

Next year's average estimate for revenue is $281.5 million. The average EPS estimate is $0.01.

Investor sentiment
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 11 members out of 14 rating the stock outperform, and three members rating it underperform. Among four CAPS All-Star picks (recommendations by the highest-ranked CAPS members), two give Tornier a green thumbs-up, and two give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Tornier is outperform, with an average price target of $26.88.

The healthcare investing landscape is littered with also-rans and a few major winners. Is Tornier the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.